메뉴 건너뛰기




Volumn 15, Issue 12, 2017, Pages 2461-2465

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COAGULATING AGENT;

EID: 85037046378     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13867     Document Type: Article
Times cited : (75)

References (30)
  • 2
    • 0025847974 scopus 로고
    • The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis
    • Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384–6.
    • (1991) Thromb Haemost , vol.66 , pp. 384-386
    • Morfini, M.1    Lee, M.2    Messori, A.3
  • 3
    • 79951472629 scopus 로고    scopus 로고
    • Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
    • Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2–10.
    • (2011) Haemophilia , vol.17 , pp. 2-10
    • Collins, P.W.1    Fischer, K.2    Morfini, M.3    Blanchette, V.S.4    Bjorkman, S.5
  • 4
    • 70349229281 scopus 로고    scopus 로고
    • Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years
    • Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years. Eur J Clin Pharmacol 2009; 65: 989–98.
    • (2009) Eur J Clin Pharmacol , vol.65 , pp. 989-998
    • Björkman, S.1    Folkesson, A.2    Jönsson, S.3
  • 5
    • 84992741171 scopus 로고    scopus 로고
    • The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A
    • McEneny-King A, Iorio A, Foster G, Edginton AN. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol 2016; 12: 1313–21.
    • (2016) Expert Opin Drug Metab Toxicol , vol.12 , pp. 1313-1321
    • McEneny-King, A.1    Iorio, A.2    Foster, G.3    Edginton, A.N.4
  • 7
    • 84873038634 scopus 로고    scopus 로고
    • Measurement of factor VIII pharmacokinetics in routine clinical practice
    • Björkman S, Collins P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11: 180–2.
    • (2013) J Thromb Haemost , vol.11 , pp. 180-182
    • Björkman, S.1    Collins, P.2
  • 8
    • 84959422310 scopus 로고    scopus 로고
    • Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization
    • Brekkan A, Berntorp E, Jensen K, Nielsen EI, Jönsson S. Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. J Thromb Haemost 2016; 14: 724–32.
    • (2016) J Thromb Haemost , vol.14 , pp. 724-732
    • Brekkan, A.1    Berntorp, E.2    Jensen, K.3    Nielsen, E.I.4    Jönsson, S.5
  • 12
    • 84900840847 scopus 로고    scopus 로고
    • Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B
    • Diao L, Li S, Ludden T, Gobburu J, Nestorov I, Jiang H. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet 2014; 53: 467–77.
    • (2014) Clin Pharmacokinet , vol.53 , pp. 467-477
    • Diao, L.1    Li, S.2    Ludden, T.3    Gobburu, J.4    Nestorov, I.5    Jiang, H.6
  • 17
    • 85019821659 scopus 로고    scopus 로고
    • Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo)
    • McEneny-King A, Foster G, Iorio A, Edginton AN. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo). JMIR Res Protoc 2016; 5: e232.
    • (2016) JMIR Res Protoc , vol.5
    • McEneny-King, A.1    Foster, G.2    Iorio, A.3    Edginton, A.N.4
  • 20
    • 84979085792 scopus 로고    scopus 로고
    • Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis
    • Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, Ewenstein BM, Oh M, Spotts G. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 2016; 22: 514–20.
    • (2016) Haemophilia , vol.22 , pp. 514-520
    • Valentino, L.A.1    Pipe, S.W.2    Collins, P.W.3    Blanchette, V.S.4    Berntorp, E.5    Fischer, K.6    Ewenstein, B.M.7    Oh, M.8    Spotts, G.9
  • 25
    • 69449088981 scopus 로고    scopus 로고
    • Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients
    • Fischer K, Pendu R, van Schooten CJ, van Dijk K, Denis CV, van den Berg HM, Lenting PJ. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009; 4: e6745.
    • (2009) PLoS ONE , vol.4
    • Fischer, K.1    Pendu, R.2    van Schooten, C.J.3    van Dijk, K.4    Denis, C.V.5    van den Berg, H.M.6    Lenting, P.J.7
  • 26
    • 84976209150 scopus 로고    scopus 로고
    • A critical appraisal of one-stage and chromogenic assays of factor VIII activity
    • Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016; 14: 248–61.
    • (2016) J Thromb Haemost , vol.14 , pp. 248-261
    • Peyvandi, F.1    Oldenburg, J.2    Friedman, K.D.3
  • 27
    • 84931956043 scopus 로고    scopus 로고
    • Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators
    • Dodt J, Hubbard AR, Wicks SJ, Gray E, Neugebauer B, Charton E, Silvester G. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.
    • (2015) Haemophilia , vol.21 , pp. 543-549
    • Dodt, J.1    Hubbard, A.R.2    Wicks, S.J.3    Gray, E.4    Neugebauer, B.5    Charton, E.6    Silvester, G.7
  • 28
    • 85020247012 scopus 로고    scopus 로고
    • Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
    • Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost 2017; 117: 1023–30.
    • (2017) Thromb Haemost , vol.117 , pp. 1023-1030
    • Iorio, A.1    Fischer, K.2    Blanchette, V.3    Rangarajan, S.4    Young, G.5    Morfini, M.6
  • 29
    • 0035216180 scopus 로고    scopus 로고
    • Ways to fit a PK model with some data below the quantification limit
    • Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481–504.
    • (2001) J Pharmacokinet Pharmacodyn , vol.28 , pp. 481-504
    • Beal, S.L.1
  • 30
    • 52549112649 scopus 로고    scopus 로고
    • Likelihood based approaches to handling data below the quantification limit using NONMEM VI
    • Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 401–21.
    • (2008) J Pharmacokinet Pharmacodyn , vol.35 , pp. 401-421
    • Ahn, J.E.1    Karlsson, M.O.2    Dunne, A.3    Ludden, T.M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.